Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 648 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Relative Bioavailability Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

NCT00416468
View directory record Official record
Conditions
Healthy
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

NCT06310304
View directory record Official record
Conditions
Healthy Participants
Interventions
Ruxolitinib IR, Ruxolitinib XR
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

NCT03357796
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

NCT03311373
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

NCT06849791
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

NCT05123079
View directory record Official record
Conditions
Healthy
Interventions
Darigabat
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700
View directory record Official record
Conditions
Autoimmune Disorder, Healthy Volunteers
Interventions
Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine

NCT00844207
View directory record Official record
Conditions
Malaria
Interventions
Fixed combination of Azithromycin and Chloroquine, Azithromycin and Chloroquine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Results available

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

NCT02783300
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3326595, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Denver, Colorado • Miami, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets

NCT01387308
View directory record Official record
Conditions
Healthy
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Sep 4, 2026, 9:05 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

NCT03137017
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

NCT07010406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Povetacicept
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

NCT00840411
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645
View directory record Official record
Conditions
Healthy Study Participants
Interventions
UCB0599, Esomeprazole, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

NCT07220551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UCB0022
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oxandrolone in Healthy Adults: A Relative Bioavailability Study

NCT03218631
View directory record Official record
Conditions
Bioavailability
Interventions
Oxandrin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 4, 2026, 9:05 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

NCT02065401
View directory record Official record
Conditions
Healthy
Interventions
Deferitazole (disodium salt, granule), Deferitazole (disodium salt, tablet), Deferitazole (magnesium hydroxide salt)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

NCT03649165
View directory record Official record
Conditions
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

NCT01648179
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

NCT02509104
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

NCT02808455
View directory record Official record
Conditions
Healthy Subjects
Interventions
(Treatment A), (Treatment B)
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 4, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

NCT02859259
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 4, 2026, 9:05 AM EDT